Song Myeong Jun
Myeong Jun Song, Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Daejeon 301-723, South Korea.
World J Gastroenterol. 2015 Apr 7;21(13):3843-9. doi: 10.3748/wjg.v21.i13.3843.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Surgery, percutaneous ablation and liver transplantation are the only curative treatment modalities for HCC. However, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options for patients with advanced HCC are required. In advanced HCC, according to current international guidelines, sorafenib, a molecular targeted agent, is the standard treatment. However, alternative treatment modalities are required because of the low response rates and unsuitability of molecular agents in real practice. In various treatment modalities, mostly in Asia, hepatic arterial infusion chemotherapy (HAIC) has been applied to advanced HCC with a view to increasing the therapeutic efficacy. HAIC provides direct drug delivery into the tumor feeding vessels and also minimizes systemic toxicities through a greater first-pass effect in the liver. However, the sample sizes of studies on HAIC have been small and large randomized trials are still lacking. In this article, we describe the treatment efficacy of HAIC for advanced stage HCC and discuss future therapeutic possibilities.
肝细胞癌（HCC）是全球最常见的癌症之一。手术、经皮消融和肝移植是HCC仅有的治愈性治疗方式。然而，大多数患者在诊断时就已患有无法切除的疾病。因此，需要为晚期HCC患者提供有效的治疗选择。在晚期HCC中，根据当前国际指南，分子靶向药物索拉非尼是标准治疗方法。然而，由于实际应用中分子药物的低反应率和不适用性，需要其他治疗方式。在各种治疗方式中，主要在亚洲，肝动脉灌注化疗（HAIC）已被应用于晚期HCC，以期提高治疗效果。HAIC可将药物直接输送至肿瘤供血血管，还可通过肝脏中更大的首过效应将全身毒性降至最低。然而，关于HAIC的研究样本量较小，目前仍缺乏大型随机试验。在本文中，我们描述了HAIC对晚期HCC的治疗效果，并探讨了未来的治疗可能性。
